224 related articles for article (PubMed ID: 2465962)
1. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders.
Mörsdorf S; Köhler M; Leipnitz G; Wenzel E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962
[TBL] [Abstract][Full Text] [Related]
2. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
3. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
Santiago-Borrero PJ; Casanova R
Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
Gill JC; Ottum M; Schwartz B
J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
[TBL] [Abstract][Full Text] [Related]
5. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
Rodeghiero F; Castaman G; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
[TBL] [Abstract][Full Text] [Related]
6. Response of patients with bleeding disorder to DDAVP administration.
Chuansumrit A; Hathirat P; Pintadit P; Isarangkura P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():174-9. PubMed ID: 7886567
[TBL] [Abstract][Full Text] [Related]
7. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.
Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM
Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487
[TBL] [Abstract][Full Text] [Related]
10. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.
Ghirardini A; Mariani G; Iacopino G; Tirindelli MC; Solinas S; Moretti T
Thromb Haemost; 1987 Oct; 58(3):896-8. PubMed ID: 3124287
[TBL] [Abstract][Full Text] [Related]
11. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
Warrier AI; Lusher JM
J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
[TBL] [Abstract][Full Text] [Related]
12. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA
Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
[TBL] [Abstract][Full Text] [Related]
13. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E
Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261
[TBL] [Abstract][Full Text] [Related]
15. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.
Lethagen S; Harris AS; Sjörin E; Nilsson IM
Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.
Mannucci PM; Vicente V; Alberca I; Sacchi E; Longo G; Harris AS; Lindquist A
Thromb Haemost; 1987 Dec; 58(4):1037-9. PubMed ID: 3127916
[TBL] [Abstract][Full Text] [Related]
17. The use of DDAVP in children with bleeding disorders.
Ben-Ami T; Revel-Vilk S
Pediatr Blood Cancer; 2013; 60 Suppl 1():S41-3. PubMed ID: 23109357
[TBL] [Abstract][Full Text] [Related]
18. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
Niessner H; Korninger C
Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
[TBL] [Abstract][Full Text] [Related]
19. [Intravenous administration of deamino-D-arginine-vasopressin (DDAVP) to patients with hemophilia A and von Willebrand's disease].
Janczarski M; Ruszkowska I; Cetnarowicz H; Lopaciuk S
Acta Haematol Pol; 1990; 21(1):16-21. PubMed ID: 2260405
[TBL] [Abstract][Full Text] [Related]
20. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.
Rose EH; Aledort LM
Ann Intern Med; 1991 Apr; 114(7):563-8. PubMed ID: 1900403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
